Utility of Cardiac Biomarkers in Predicting Infarct Size, Left Ventricular Function, and Clinical Outcome After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction

JACC: Cardiovascular Interventions

Volumn 1, Issue 4, 2008, Pages 415-423

  Chia, Stanley ^a   Senatore, Fred ^b   Raffel, O Christopher ^a   Lee, Hang ^a   Wackers, Frans J Th ^c   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Mitsubishi Pharma America Inc   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angioplasty; cardiac biomarkers; infarct size myocardial infarction; ventricular function

Indexed keywords

BIOCHEMICAL MARKER; CARDIOVASCULAR AGENT; CREATINE KINASE; CREATINE KINASE MB; MCC 135; PLACEBO; TROPONIN I; TROPONIN T;

ACCURACY; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION; TIME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BENZENESULFONATES; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CREATINE KINASE, MB FORM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; STROKE VOLUME; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; TROPONIN I; TROPONIN T; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 49449083154     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.04.010     Document Type: Article

References (23)

1. Hackel D.B., Reimer K.A., Ideker R.E., et al. Comparison of enzymatic and anatomic estimates of myocardial infarct size in man. Circulation 70 (1984) 824-835
2. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
3. Jaffe A.S., Ravkilde J., Roberts R., et al. It's time for a change to a troponin standard. Circulation 102 (2000) 1216-1220
4. Turer A.T., Mahaffey K.W., Gallup D., et al. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med 6 (2005) 12
5. Gibbons R.J., Valeti U.S., Araoz P.A., and Jaffe A.S. The quantification of infarct size. J Am Coll Cardiol 44 (2004) 1533-1542
6. Licka M., Zimmermann R., Zehelein J., et al. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 87 (2002) 520-524
7. Steen H., Giannitsis E., Futterer S., Merten C., Juenger C., and Katus H.A. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 48 (2006) 2192-2194
8. Giannitsis E., Steen H., Kurz K., et al. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T. J Am Coll Cardiol 51 (2008) 307-314
9. Jang I.K., Pettigrew V., Picard M.H., et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis 20 (2005) 147-153
10. Jang I.K., Weissman N.J., Picard M.H., et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J 155 (2008) 113.e1-113.e8
11. DePuey G.E. Imaging Guidelines for Nuclear Cardiology Procedures. Menu: "Manage Your Practice: Guidelines and Standards" 2006. http://www.asnc.org Accessed November 13, 2007
12. Liu Y.H., Sinusas A.J., DeMan P., Zaret B.L., and Wackers F.J. Quantification of SPECT myocardial perfusion images: methodology and validation of the Yale-CQ method. J Nucl Cardiol 6 (1999) 190-204
13. Liu Y.H., Sinusas A.J., Khaimov D., Gebuza B.I., and Wackers F.J. New hybrid count- and geometry-based method for quantification of left ventricular volumes and ejection fraction from ECG-gated SPECT: methodology and validation. J Nucl Cardiol 12 (2005) 55-65
14. Baardman T., Hermens W.T., Lenderink T., et al. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme substudy. Eur Heart J 17 (1996) 237-246
15. Christenson R.H., Vollmer R.T., Ohman E.M., et al. Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI study group. Am J Cardiol 85 (2000) 543-547
16. Halkin A., Stone G.W., Grines C.L., et al. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 47 (2006) 951-961
17. Ibrahim T., Bülow H.P., Hackl T., et al. Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction. J Am Coll Cardiol 49 (2007) 208-216
18. Tsung S.H. Several conditions causing elevation of serum CK-MB and CK-BB. Am J Clin Pathol 75 (1981) 711-715
19. Bertinchant J.P., Larue C., Pernel I., et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem 29 (1996) 587-594
20. Ohlmann P., Monassier J.P., Michotey M.O., et al. Troponin I concentrations following primary percutaneous coronary intervention predict large infarct size and left ventricular dysfunction in patients with ST-segment elevation acute myocardial infarction. Atherosclerosis 168 (2003) 181-189
21. Leoncini M., Bellandi F., Sciagra R., et al. Gated SPECT evaluation of the relationship between admission troponin I, myocardial salvage, and functional recovery in acute myocardial infarction treated by abciximab and early primary angioplasty. J Nucl Med 45 (2004) 739-744
22. Ohlmann P., Jaquemin L., Morel O., et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction. Am Heart J 152 (2006) 1161-1167
23. Younger J.F., Plein S., Barth J., Ridgway J.P., Ball S.G., and Greenwood J.P. Troponin-I concentration 72 hours after myocardial infarction correlates with infarct size and presence of microvascular obstruction. Heart 93 (2007) 1547-1551